NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with EGFR-mutated metastatic NSCLC, without CNS metastases on brain MRI and without the ABCG2 34G>A SNP, treated with osimertinib as part of regular care are eligible for inclusion. Participants have at least radiologically proven stable disease (SD) or better on regular care osimertinib therapy.
1 total trials
Filter these 1 trials by phase, country, sponsor and more.